Century Therapeutics, Inc. IPSC

1.67 (0.02) (1.18%) as of 25 Sep
Market cap
$306.0M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — — — 0.00 0.00 0.00 0.00
P/S ratio
— — — — 55.21 96.60 12.06 0.75
P/FCF ratio
— — — — 0.00 0.00 0.00 0.00
P/Operating CF
— — — — (12.53) (8.23) (3.28) (5.38)
P/B ratio
— — — — 0.95 1.17 0.49 0.54
Price to Tangible BV
— — — — 0.95 1.17 0.62 0.69
EV/Sales
— — — — (3.20) 19.60 (16.66) (0.27)
EV/EBITDA
— — — — 0.13 0.00 0.85 4.68
EV/Operating CF
— — — — (1.18) (0.50) 1.00 0.29
EV/FCF
— — — — 1.00 (0.43) 1.00 0.29
Quick Ratio
— 27.28 6.25 14.24 10.58 9.68 1.46 5.79
Current Ratio
— 28.10 6.51 14.57 10.72 9.92 1.50 5.97
Net Debt/EBITDA
— 4.12 1.26 2.31 2.43 1.25 1.46 17.95
Debt/Assets
0.00% 0.00% 9.25% 2.96% 2.43% 0.18% 0.02% 0.01%
Debt/Equity
— 0.00 0.13 0.03 0.04 0.00 0.00 0.00
Asset Turnover
— 0.00 0.00 0.00 0.01 0.01 0.02 0.38
Operating CF/Net income
— 0.07 0.77 0.93 (0.11) 0.65 0.87 10.84
Capex/Depreciation
— 0.00 (6.58) (11.09) (3.50) (1.50) (0.02) (0.08)
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— (186.03%) 83.53% (66.13%) (37.46%) (56.07%) (73.14%) (5.98%)
ROA
— (304.26%) (40.03%) (35.22%) (28.34%) (32.26%) (35.46%) (3.32%)
ROIC
— 0.00% (450.83%) (31.83%) 0.00% (723.93%) 0.00% (25.79%)
Return on Tangible Assets
— (292.73%) (65.28%) (35.43%) (35.13%) (59.20%) (100.12%) (6.36%)
Average Days of Receivables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
— 0.00% 0.00% 0.00% 2,061.42% 4,371.81% 1,627.62% 87.64%
Selling, General and Administrative Expense of Revenue
— 0.00% 0.00% 0.00% 612.75% 1,552.84% 503.19% 21.99%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.15
Share Based Compensation of Revenue
— — 0.00% 0.00% 205.21% 654.23% 192.56% 6.27%
Graham Net Nets
— — — — 0.47 0.00 0.03 0.65
Graham Number
— — — — 0.00 0.00 0.00 0.00
Earnings Yield
— — — — (45.88%) (62.91%) (161.39%) (14.00%)
Free Cash Flow Yield
— — — — (5.77%) (47.28%) (138.84%) (120.99%)
Revenue per Share
— 0.00 0.00 0.00 0.09 0.04 0.08 1.26
Operating CF per Share
— (0.29) (5.52) (2.75) 0.24 (1.49) (1.40) (1.20)
Capex per Share
— 0.00 (1.31) (1.39) (0.53) (0.23) 0.00 (0.01)
Free Cash Flow per Share
— (0.29) (6.83) (4.14) (0.29) (1.72) (1.40) (1.21)
Cash per Share
— 1.49 10.12 6.88 5.46 2.91 2.41 1.35
Shareholders Equity per Share
— 2.88 9.80 12.23 5.24 3.11 2.05 1.84
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 2.88 9.80 12.23 5.24 3.11 2.05 1.84
Free Cash Flow
— (16.17) (51.09) (133.97) (16.55) (102.08) (110.29) (104.72)
Working Capital
— 81.13 66.69 212.50 289.90 159.15 64.27 100.54
Capital Expenditures
— (2.46) (9.82) (44.97) (30.60) (13.74) (0.15) (0.85)
Net Current Asset Value
— 81.13 45.37 187.02 135.92 1.05 2.20 56.00
EV/EBIT
— — — — 0.12 0.00 0.79 1.77
Capex to Sales
— — 0.00 0.00 5.89 6.15 0.02 0.01
Net Profit Margin
— 0.00% 0.00% 0.00% (2,518.41%) (6,115.12%) (1,920.87%) (8.78%)
Price to Operating Income
— — — — 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
— 0.10 0.10 0.07 0.11 0.13 0.14 0.21
Cash ROIC
— (7.79%) (35.64%) (23.25%) (10.91%) (44.69%) (49.12%) (55.75%)
Accounts Receivable Turnover
— 0.00 0.00 0.00 10.10 0.00 0.00 0.00
Accounts Payable Turnover
— 0.05 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 0.00 0.00 0.00 — — —
Average Days of Payables
— 2,269.16 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 0.00 0.00 0.00 — — —
Average Receivables
— 0.52 0.52 0.58 0.52 — — —
Average Payables
— 4.82 4.82 7.84 6.53 4.10 2.91 3.92
Average Assets
— 80.45 133.84 272.08 461.96 423.62 356.95 288.46
Average Common Equity
— 131.58 (64.14) 144.91 349.49 243.74 173.06 160.15

Fold the line items

Columns are period end dates